Media.Player

Nanoparticles of Curcumin for Treating Cancer or Infection

Summary

Curcumin has long been shown to exhibit therapeutic potential for treating cancer, infections and Alzheimer’s disease, however its low water solubility significantly limits its oral absorption to achieve therapeutic effectiveness. Our novel drug formulation technique provides a pragmatic means for producing curcumin naonoparticles to address this problem.

Supplementary Information

Inventor: LAU, Allan Sy | YANG, Lai Hung, Cindy | OR, Cho Tsun | LAW, Hing Yee
Priority Number: WO2011070415A1
IPC Current: A61K0031343 | A61P001100 | A61P001702 | A61P001902 | A61P002900 | A61P003702 | A61P003706
Assignee Applicant: Purapharm International (HK) Limited | Versitech Limited
Title: NOVEL THERAPEUTIC METHODS FOR TREATING INFLAMMATION AND IMMUNE SYSTEM DISORDERS | NOUVELLE MÉTHODE THÉRAPEUTIQUE POUR LE TRAITEMENT D'ÉTATS INFLAMMATOIRES ET DE TROUBLES DU SYSTÈME IMMUNITAIRE
Usefulness: NOVEL THERAPEUTIC METHODS FOR TREATING INFLAMMATION AND IMMUNE SYSTEM DISORDERS | NOUVELLE MÉTHODE THÉRAPEUTIQUE POUR LE TRAITEMENT D'ÉTATS INFLAMMATOIRES ET DE TROUBLES DU SYSTÈME IMMUNITAIRE
Summary: For treating a subject to reduce inflammation or to modulate an immune response; or having a condition associated with tumor necrosis factor α overproduction, where the subject is a human (claimed); to reduce nitric oxide production; TNF-α mRNA stability; to treat a condition selected from infection, inflammation caused by an environmental toxin, an autoimmune condition, neurodegenerative disease, cardiovascular disease, cerebrovascular disease, intestinal inflammation, post-infection associated neurological neuralgia, shingles, chronic fatigue syndrome, inflammation caused by concurrent infection or immunological over-reaction to pathogen invasion, allergy, graft rejection, pathological immune cell proliferation or activity, and respiratory inflammation; to treat a condition selected from ischemic stroke, rheumatoid arthritis, psoriasis, cardiovascular disease, cerebrovascular disease, inflammatory bowel disorder, septic shock, graft vs host rejection, varicella zoster infection, herpes simplex infection, cytomegalovirus infection, herpes simplex virus-8 infection, neuralgia, and neurasthenia associated with herpes zoster reactivation; to treat or ameliorate inflammation associated with atherosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular inflammatory disorders including cerebro-vascular disease (stroke), respiratory distress syndrome and other cardiopulmonary diseases; and to treat or ameliorate inflammation associated with peptic ulcer; ulcerative colitis, Crohn's Disease, irritable bowel syndrome, other inflammatory bowel conditions, and other diseases, conditions or disorders of the gastrointestinal tract; to treat or ameliorate inflammation associated with herpes zoster (shingles); posterior uveitis; intermediate uveitis; anterior uveitis; conjunctivitis; chorioretinitis; uveoretinitis; optic neuritis; intraocular inflammation, such as retinitis and cystoid macular edema; sympathetic ophthalmia; scleritis; retinitis pigmentosa; immune and inflammatory components of degenerative fondus disease; inflammatory components of ocular trauma; ocular inflammation caused by infection; proliferative vitreoretinopathies; acute ischemic optic neuropathy; excessive scarring; immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, conditions or disorders.

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

11/MED/421a

Others

Inventor(s): Professor Albert Chow and Professor Larry BAUM, School of Pharmacy Licensing Status: Available

Country/Region

Hong Kong